Adherium appoints digital health pioneer to lead European business development

Digital health veteran to join expanding global team

Adherium, a leader in digital health technologies that addresses sub-optimal medication use in chronic disease, has appointed Scott Fleming as its senior vice president of business development for Europe.

John Tarplee stepped down from the role at the end of December 2016 to pursue a new venture.

Fleming is a founding member of the digital drug delivery movement.

With 25 years’ sector experience covering strategy, device development, sales and marketing and big pharma, he brings valuable commercial knowledge and will continue to develop Adherium’s partnerships within the key European markets.

After gaining an interest in drug delivery, particularly inhaled and needle-free delivery, at PA Consulting in the US, Fleming co-founded MicroDose Therapeutx in 1997, developing the first totally-digital piezo-driven dry powder inhaler, which was then licensed to big pharma.

During his tenure as senior vice president, he led MicroDose’s strategy and executed numerous licensing and development collaborations with Bristol-Myers Squibb Company, Novartis International AG, Merck & Co, and Gilead Sciences among others, for respiratory programmes using the digital inhaler and associated in-house molecules.

Fleming engineered the sale of MicroDose to Teva Pharmaceutical Industries in 2013, and subsequently took on a key role as the global brand lead for eConnectivity of Teva’s respiratory franchise based in Amsterdam.

There he was responsible for the commercial and branding strategy for eConnectivity of Teva’s branded inhaler products, including the acquired MicroDose technology, supporting the development and future launches of these products.

Fleming is also a listed inventor on numerous patents and his research in the field of digital drug delivery has been published in peer-reviewed journals.

In addition, he has presented data at sector conferences.

In his new role, Fleming will be based in Amsterdam, where Adherium’s European operations will now be based and will continue to develop Adherium’s partnerships within the key European market and beyond.

Commenting on the position, Garth Sutherland, chief executive of Adherium said: “Bringing a pioneer of the digital health movement into our business is an exciting development as we continue to build our commercial capabilities, particularly in Europe.”

Fleming added:“Having first collaborated with Adherium nine years ago, working to enable data capture to the cloud, it is great to now be joining the team.

“I have watched Adherium’s technology grow to play a vital role providing key clinical data proofs for the digital drug delivery industry.

“I look forward to using my experience in this space to build on Adherium’s capabilities, reaching more patients and improving adherence and outcomes.”

Companies